Cogent Biosciences (COGT)
(Delayed Data from NSDQ)
$7.56 USD
-0.36 (-4.55%)
Updated May 10, 2024 04:00 PM ET
After-Market: $7.55 -0.01 (-0.13%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Cogent Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 266 | 261 | 220 | 242 | 37 |
Receivables | 0 | 0 | 0 | 0 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 4 | 3 | 3 | 1 |
Total Current Assets | 271 | 265 | 223 | 245 | 41 |
Net Property & Equipment | 8 | 8 | 2 | 0 | 2 |
Investments & Advances | 7 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 5 | 5 | 1 | 2 |
Total Assets | 313 | 301 | 232 | 251 | 49 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 11 | 6 | 3 | 1 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 26 | 18 | 8 | 5 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 2 | 3 | 6 | 1 |
Total Current Liabilities | 38 | 27 | 17 | 13 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 56 | 45 | 18 | 16 | 18 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 60 | 66 | 85 | 111 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 801 | 601 | 400 | 322 | 156 |
Retained Earnings | -604 | -411 | -271 | -199 | -124 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 258 | 256 | 214 | 235 | 32 |
Total Liabilities & Shareholder's Equity | 313 | 301 | 232 | 251 | 49 |
Total Common Equity | 198 | 190 | 129 | 124 | 32 |
Shares Outstanding | 86.12 | 69.89 | 39.80 | 32.30 | 7.60 |
Book Value Per Share | 2.30 | 2.72 | 3.24 | 3.83 | 4.18 |
Fiscal Year End for Cogent Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 266 | 279 | 329 | 222 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 5 | 7 | 5 | 5 |
Total Current Assets | NA | 271 | 286 | 335 | 226 |
Net Property & Equipment | NA | 8 | 9 | 9 | 9 |
Investments & Advances | NA | 7 | 34 | 22 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 5 | 5 | 5 | 5 |
Total Assets | NA | 313 | 355 | 392 | 263 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 11 | 10 | 7 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 26 | 24 | 17 | 16 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 38 | 35 | 26 | 21 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 56 | 53 | 44 | 40 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 60 | 60 | 62 | 62 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 801 | 792 | 780 | 611 |
Retained Earnings | NA | -604 | -549 | -494 | -450 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 258 | 303 | 348 | 224 |
Total Liabilities & Shareholder's Equity | NA | 313 | 355 | 392 | 263 |
Total Common Equity | 0 | 198 | 243 | 286 | 161 |
Shares Outstanding | 95.61 | 86.12 | 85.40 | 70.90 | 70.90 |
Book Value Per Share | 0.00 | 2.30 | 2.84 | 4.04 | 2.27 |